PELLEGRINO, BENEDETTA
 Distribuzione geografica
Continente #
NA - Nord America 739
EU - Europa 530
AS - Asia 317
AF - Africa 14
SA - Sud America 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 1.614
Nazione #
US - Stati Uniti d'America 729
IE - Irlanda 185
SG - Singapore 154
CN - Cina 146
IT - Italia 118
SE - Svezia 118
DE - Germania 35
AT - Austria 19
CI - Costa d'Avorio 12
FI - Finlandia 12
BE - Belgio 10
BR - Brasile 10
CA - Canada 10
GB - Regno Unito 8
CZ - Repubblica Ceca 7
IN - India 5
FR - Francia 4
ES - Italia 3
LT - Lituania 3
NL - Olanda 3
PL - Polonia 3
TR - Turchia 3
A1 - Anonimo 2
AL - Albania 2
HK - Hong Kong 2
ZA - Sudafrica 2
BD - Bangladesh 1
EC - Ecuador 1
ID - Indonesia 1
IR - Iran 1
JP - Giappone 1
KZ - Kazakistan 1
PH - Filippine 1
QA - Qatar 1
VE - Venezuela 1
Totale 1.614
Città #
Dublin 185
Chandler 179
Singapore 127
Santa Clara 108
Shanghai 55
Boardman 54
Ashburn 51
New York 49
Beijing 35
Ann Arbor 23
Princeton 22
Bremen 21
Vienna 19
Seattle 18
Dearborn 13
Des Moines 13
Parma 13
Abidjan 12
Helsinki 12
Milan 10
Ardea 8
Brussels 8
Wilmington 8
Ravenna 7
Los Angeles 6
Bologna 5
Falls Church 5
Olomouc 5
Rio Saliceto 5
Toronto 5
Cascina 4
Nanjing 4
Pavia 4
Reggio Emilia 4
Rome 4
Fairfield 3
Hangzhou 3
Kunming 3
Montreal 3
Nanchang 3
Shenzhen 3
Verona 3
Woodbridge 3
Bastia umbra 2
Brooklyn 2
Capriate San Gervasio 2
Frankfurt am Main 2
Hebei 2
Izmir 2
Jinan 2
London 2
Madrid 2
Marseille 2
Menlo Park 2
Munich 2
Scarperia e San Piero 2
Stockholm 2
Tirana 2
Trento 2
Almaty 1
Amsterdam 1
Andover 1
Ardabil 1
Augusta 1
Borås 1
Brno 1
Buíque 1
Caracas 1
Chongqing 1
Corno di Rosazzo 1
Council Bluffs 1
Curitiba 1
Divinópolis 1
Doha 1
Durban 1
Edinburgh 1
Fremont 1
Gambettola 1
Governador Valadares 1
Grafing 1
Guangzhou 1
Guiyang 1
Hefei 1
Hong Kong 1
Huizen 1
Imola 1
Jakarta 1
Johannesburg 1
Kocaeli 1
Leuven 1
Manila 1
Modena 1
Molenbeek-Saint-Jean 1
Nanning 1
Naples 1
Newark 1
Piacenza 1
Pinhais 1
Porto Seguro 1
Prague 1
Totale 1.198
Nome #
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 83
Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature 82
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 82
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 70
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 69
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 68
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 66
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 62
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 62
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 61
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 58
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 57
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 55
A review of immune checkpoint blockade in breast cancer 54
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 52
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 52
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 51
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 50
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 48
My best choice after a round trip from illness 45
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 45
A narrative review of the principal glucocorticoids employed in cancer 45
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors 44
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 43
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 38
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 36
The Innate Immune Microenvironment in Metastatic Breast Cancer 34
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 32
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 21
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 19
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study 18
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 18
RAD51 as a biomarker for homologous recombination deficiency in high-grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test 18
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 17
BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors 15
Totale 1.670
Categoria #
all - tutte 8.597
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.597


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202071 0 0 0 0 0 11 5 2 2 40 10 1
2020/202189 2 8 1 5 6 14 15 12 4 6 13 3
2021/202296 1 2 6 7 5 6 7 5 2 8 0 47
2022/2023652 49 66 33 48 70 71 4 47 214 4 38 8
2023/2024335 13 29 6 4 26 74 34 41 13 28 29 38
2024/2025395 36 40 59 52 113 95 0 0 0 0 0 0
Totale 1.670